{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:38:40Z","timestamp":1791121120535,"version":"4.1.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":5509,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,8]]},"DOI":"10.1046\/j.1365-2133.2000.03656.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T05:29:37Z","timestamp":1047360577000},"page":"313-319","source":"Crossref","is-referenced-by-count":79,"title":["Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL"],"prefix":"10.1093","volume":"143","author":[{"given":"O.","family":"Zoi-Toli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.H.","family":"Vermeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"De Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Van Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.J.L.M.","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Willemze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB1","first-page":"354","article-title":"EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer","volume":"90","author":"Willemze","year":"1997","journal-title":"Blood"},{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB2","first-page":"1169","article-title":"Prognostic significance of CD30 (Ki-1\/Ber-H2) expression in primary cutaneous large-cell lymphomas of T-cell origin. A clinicopathologic and immunohistochemical study in 20 patients","volume":"135","author":"Beljaards","year":"1989","journal-title":"Am J Pathol"},{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB3","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1126\/science.7518614","article-title":"Fas and perforin pathways as major mechanisms of T-cell-mediated cytotoxicity","volume":"265","author":"Kagi","year":"1994","journal-title":"Science"},{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0952-7915(98)80222-7","article-title":"Mechanisms of CD95 (APO-1\/Fas)-mediated apoptosis","volume":"10","author":"Peter","year":"1998","journal-title":"Curr Opin Immunol"},{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB5","first-page":"847","article-title":"Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin\u2019s lymphomas and Hodgkin\u2019s disease","volume":"148","author":"Nguyen","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB6","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/ijc.2910570314","article-title":"Expression of APO-1 (CD95), a member of the NGF\/TNF receptor superfamily, in normal and neoplastic colon epithelium","volume":"57","author":"Moller","year":"1994","journal-title":"Int J Cancer"},{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB7","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/nm1296-1361","article-title":"Lymphocyte apoptosis induced by CD95 (APO-1\/Fas) ligand-expressing tumor cells-a\u00a0mechanism of immune evasion?","volume":"2","author":"Strand","year":"1996","journal-title":"Nature Med"},{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1600-0560.1999.tb01805.x","article-title":"Apoptosis, Fas and Fas-ligand expression in melanocytic tumors","volume":"26","author":"Sprecher","year":"1999","journal-title":"J Cutan Pathol"},{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/(SICI)1096-9896(199912)189:4<533::AID-PATH473>3.0.CO;2-3","article-title":"Prognostic significance of Fas and Fas-ligand expression in cutaneous B-cell lymphomas","volume":"189","author":"Zoi-Toli","year":"1999","journal-title":"J Pathol"},{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nm0198-031","article-title":"Downregulation of Fas ligand by shedding","volume":"4","author":"Tanaka","year":"1998","journal-title":"Nature Med"},{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB11","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/00002371-199310000-00011","article-title":"Fas\/APO-1 expression and function on malignant cells of hematologic and nonhematologic origin","volume":"14","author":"Owen-Schaub","year":"1993","journal-title":"J Immunother"},{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB12","first-page":"330","article-title":"Expression of Bcl-2 protein and Fas antigen in non-Hodgkin\u2019s lymphomas","volume":"145","author":"Kondo","year":"1994","journal-title":"Am J Pathol"},{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2559.1995.tb00215.x","article-title":"Frequent expression of FAS\/APO-1 in Hodgkin\u2019s disease and anaplastic large cell lymphomas","volume":"27","author":"Xerri","year":"1995","journal-title":"Histopathology"},{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB14","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/sj.leu.2400815","article-title":"Malignant and reactive cells from human lymphomas frequently express Fas ligand but display a different sensitivity to Fas-mediated apoptosis","volume":"11","author":"Xerri","year":"1997","journal-title":"Leukemia"},{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB15","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1600-0560.1998.tb01766.x","article-title":"Comparative analysis of histological and immunohistological features in mycosis fungoides and S\u00e9zary syndrome","volume":"25","author":"Kamarashev","year":"1998","journal-title":"J Cutan Pathol"},{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB16","first-page":"369","article-title":"Fas ligand expression in nodal non-Hodgkin\u2019s lymphoma","volume":"11","author":"Mullauer","year":"1998","journal-title":"Mod Pathol"},{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB17","first-page":"60","article-title":"Patients with systemic lupus\u00a0erythematosus with high plasma levels of sFas risk relapse","volume":"26","author":"Lopik van","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB18","first-page":"1007","article-title":"Human lung carcinomas express Fas ligand","volume":"57","author":"Niehans","year":"1997","journal-title":"Cancer Res"},{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB19","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/33712","article-title":"Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells","volume":"392","author":"Tollefson","year":"1998","journal-title":"Nature"},{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/40657","article-title":"Inhibition of death receptor signals by cellular FLIP","volume":"388","author":"Irmler","year":"1997","journal-title":"Nature"},{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB21","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0002-9440(10)65372-2","article-title":"Expression of cytotoxic proteins by neoplastic T-cells in mycosis fungoides increases with progression from plaque stage to tumor stage disease","volume":"154","author":"Vermeer","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB22","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/4779","article-title":"Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells","volume":"5","author":"Bossi","year":"1999","journal-title":"Nature Med"},{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB23","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.4049\/jimmunol.154.8.3806","article-title":"Expression of the Fas ligand in cells of T-cell lineage","volume":"154","author":"Suda","year":"1995","journal-title":"J Immunol"},{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB24","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1126\/science.274.5291.1363","article-title":"Melanoma cell expression of Fas (Apo-1\/CD95) ligand: implications for tumor immune escape","volume":"274","author":"Hahne","year":"1996","journal-title":"Science"},{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB25","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1084\/jem.184.3.1075","article-title":"The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand","volume":"104","author":"O\u2019Connell","year":"1996","journal-title":"J Exp Med"},{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB26","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1172\/JCI119273","article-title":"Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?","volume":"99","author":"Saas","year":"1997","journal-title":"J\u00a0Clin Invest"},{"key":"10.1046\/j.1365-2133.2000.03656.x-BIB27","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/3965","article-title":"Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells","volume":"4","author":"Desbarats","year":"1998","journal-title":"Nature Med"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2133.2000.03656.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1046\/j.1365-2133.2000.03656.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T04:39:01Z","timestamp":1682051941000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/143\/2\/313\/6687969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,8]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,8]]}},"URL":"https:\/\/doi.org\/10.1046\/j.1365-2133.2000.03656.x","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,8]]}}}